MAP3K13 is altered in 1.50% of all cancers with breast invasive ductal carcinoma, squamous cell lung carcinoma, lung adenocarcinoma, colon adenocarcinoma, and cutaneous melanoma having the greatest prevalence of alterations .
The most common alterations in MAP3K13 are MAP3K13 Amplification (0.60%), MAP3K13 Loss (0.02%), MAP3K13 R278C (0.02%), MAP3K13 A465V (0.01%), and MAP3K13 A189V (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.